Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-Dose Terbinafine vs Butenafine in Tinea Pedis
NCT03999437Phase 2Unknown
- Sponsor
- The United Laboratories International Holdings
- Start
- Jan 2019
- Primary completion
- Dec 2019
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Terbinafine subungual gel and butenafine in tinea pedis (3 arms), sponsored by The United Laboratories International Holdings. Primary endpoint: Proportion of participants with effective treatment at week 6. Status: unknown.
02
Drugs
Terbinafine subungual gelbutenafine
03
Conditions
tinea pedis
Beyond the preview
Go deeper on NCT03999437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03999437.